Nasofan (Fluticasone Propionate)

Fluticasone propionate activates glucocorticoid receptors in the cells lining the nasal mucosa. This activation suppresses the transcription of inflammatory cytokines, limits the migration of inflammatory cells, and decreases vascular permeability, thereby reducing swelling and mucus production in the nose.

The specific dosing regimen for Nasofan is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and response to therapy. The prescriber will provide detailed instructions on the number of sprays per nostril and frequency of use.

Safety data for fluticasone propionate in pregnancy and lactation are limited. Healthcare providers generally weigh the potential benefits against any possible risks. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their physician before starting treatment.

To place an order, submit an enquiry on the Nasofan product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nasofan’s active ingredient, fluticasone propionate, is a high‑potency corticosteroid with minimal systemic absorption when used as directed, offering effective symptom control with a low risk of systemic side effects. Compared with older agents such as beclomethasone, fluticasone generally provides longer duration of action and a more favorable safety profile for long‑term use.

Nasofan should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the bottle tightly closed when not in use and avoid exposing it to extreme temperatures, which could affect spray performance.

Nasofan is administered intranasally. The user should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. The process is then repeated in the other nostril if directed by the prescriber.

Serious risks, though uncommon, include local fungal infections of the nasal mucosa, adrenal suppression with prolonged high‑dose use, severe allergic reactions such as anaphylaxis, and ocular complications like cataracts or glaucoma. Patients should seek immediate medical attention if they experience unusual bleeding, persistent sore throat, visual changes, or signs of a systemic allergic reaction.

Nasofan should be avoided in individuals with known hypersensitivity to fluticasone propionate or any component of the formulation. It is also contraindicated in patients with active untreated bacterial, fungal, or viral infections of the nasal passages, and in those who have recently undergone nasal surgery or trauma unless cleared by a physician.